Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Driehaus Capital Management
AddedFeb 13, 2024
UpdatedJun 28, 2026
Driehaus Capital Management

Driehaus Capital Management

Operating

Driehaus Capital Management: Global investment management and advisory firm specializing in diverse strategies.

Location
Chicago, IL, US
Founded
1982
Firm
Compare
Portfolio
Employees
Website

Driehaus Capital Management is an independent boutique investment adviser specializing in long-only equity and multi-asset alternative strategies. The firm manages global, emerging markets, U.S. growth equity, and alternative investment strategies, offering a diverse range of investment options for clients.

Notable portfolio companies include Astria Therapeutics, Crinetics Pharmaceuticals, and Frontier Medicines in the biotech sector. Driehaus has invested across various stages, from seed to post-IPO equity rounds, demonstrating flexibility in their investment approach. The firm's expertise spans multiple industries, with a particular focus on healthcare and technology sectors.

Driehaus Capital Management - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments17
Current Portfolio Count12
Total Portfolio Exits4

Top Investment Stages

Post Ipo Equity6 (40.0%)
Series B5 (33.3%)
Series Unknown2 (13.3%)
Seed1 (6.7%)
Series C1 (6.7%)

Stage Mix

Post Ipo Equity 40%Series B 33%Series Unknown 13%Seed 7%Series C 7%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Astria Therapeutics logo

Astria Therapeutics

Septerna logo

Septerna

Sonendo logo

Sonendo

Maze Therapeutics logo

Maze Therapeutics

Frontier Medicines logo

Frontier Medicines

NeoGenomics Laboratories logo

NeoGenomics Laboratories

Crinetics Pharmaceuticals logo

Crinetics Pharmaceuticals

X4 Pharmaceuticals logo

X4 Pharmaceuticals

Vividion Therapeutics logo

Vividion Therapeutics

DarioHealth logo

DarioHealth

Thrive Earlier Detection logo

Thrive Earlier Detection

Pulmonx logo

Pulmonx

Peloton Therapeutics logo

Peloton Therapeutics

Ideaya Biosciences logo

Ideaya Biosciences

Trace.com logo

Trace.com

Alloptic logo

Alloptic

Driehaus Capital Management - Classification

Also Known As
  • Driehaus Capital Management LLC
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
ISIC
  • 6430Trusts, funds and similar financial entities
Show 8 more industry codes
NAICS
  • 525900Other Investment Pools and Funds
  • 525990Other Financial Vehicles
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
SIC
  • 6726Unit Investment Trusts, Face-amount Certificate Offices
  • 6000Depository Institutions
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified